CAPTRUST Financial Advisors
RNAC icon

CAPTRUST Financial Advisors’s Cartesian Therapeutics RNAC Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50
Closed -$2K – 3637
2022
Q2 		$2K Buy
+50
New +$1.48K ﹤0.01% 4504

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

CAPTRUST Financial Advisors's RNAC Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Cartesian Therapeutics (RNAC) in Q3 2022, closing a stake of 50 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in RNAC in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 96 funds tracked by Wall St. Rank hold RNAC as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Cartesian Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 50 Cartesian Therapeutics shares in Q3 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Cartesian Therapeutics in Q2 2022 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Cartesian Therapeutics position peaked at $2K in Q2 2022.
  • 96 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.